The endothelins are among the most potent vasoconstrictors known. Pharmacological inhibition of endothelin receptors lowers blood pressure (BP). It is unknown whether naturally occurring genetic variation in the endothelin receptors influences BP. We have evaluated the type A endothelin receptor (EDNRA) as a candidate gene for hypertension in a large family study. A total of 1425 members of 248 families selected via a proband with hypertension were studied. Ambulatory BP monitoring was conducted using the A&D TM2421 device. Four haplotype-tagging single nucleotide polymorphisms (SNPs) spanning the EDNRA gene were typed. There was evidence of association between genotype at the rs5335 (C þ 70G) SNP and night systolic blood pressure ( þ 1.24% (s.e. 0.64) per G allele; P ¼ 0.05); night diastolic blood pressure ( þ 1.64% (s.e. 0.71) per G allele; P ¼ 0.021) and night mean BP ( þ 1.51% (s.e. 0.64) per G allele; P ¼ 0.017). Borderline significant trends in the same direction were seen for daytime BPs. Proportions of hypertensives in each of the three genotype groups were C/C 34.7%, C/G 37.9%, G/G 42.4% yielding an odds ratio for hypertension per G allele of 1.19 (95% confidence interval 1.00-1.41; P ¼ 0.05). In conclusion, the rs5335 (C þ 70G) polymorphism of the EDNRA gene has small effects on the risk of hypertension. Natural variation in other genes in the endothelin-signalling pathway should be explored to identify additional influences on BP regulation.
Introduction
Hypertension is a multifactorial complex disorder involving interactions between genetic and environmental factors. Familial, twin and adoption studies attribute about 20-40% of the total variation in blood pressure (BP) to genetic influences. 1 However, identification of the genes responsible for hypertension has been very challenging, probably because of the small size of most of the genetic effects that are likely to be present, and the pathophysiological heterogeneity of the condition. Case-control studies of hypertension as a 'disease state' introduce an artificial dichotomy into the analysis of a quantitative trait that may result in substantial loss of power to detect genetic effects. However, BP as a quantitative trait presents specific difficulties as a phenotype for study, because of the very considerable uncertainty in estimating an individual's 'usual' BP from a limited number of measurements. Ambulatory blood pressure measurement (ABPM) has been shown to provide more reproducible estimates of individuals' 'usual' BPs than isolated clinical readings, and the ABPM approach therefore has potential to increase the power of genetic studies. 2, 3 An additional methodological concern specific to genetic association studies conducted in unrelated individuals is that of population stratification (that is, unsuspected heterogeneity in ancestry between the case and control group) as a cause of a falsepositive or false-negative result. Although the precise impact of stratification on most published case-control studies is unquantified, it has been shown that sufficient population substructure exists in apparently ethnically homogeneous US populations to potentially lead to false-positive results in such studies. [4] [5] [6] By contrast with studies in unrelated individuals, family-based studies avoid potential problems due to stratification.
The endothelins constitute a family of 21 amino-acid peptides and are considered to be the most potent vasoconstrictors synthesized by endothelial and vascular smooth muscle cells. Their production and release are stimulated by many factors including hormones (adrenalin, angiotensin II, arginine: vasopressin and cortisol), metabolic factors (glucose, low-density lipoprotein cholesterol), growth factors (cytokines, transforming growth factor-b, insulinlike growth factors), hypoxia and shear stress on the vascular wall. Among the three endothelin proteins ET-1, ET-2 and ET-3, endothelin-1 (ET-1) is the most abundant. It is produced by vascular cells, and mediates its effect by acting either on A or B receptor subtypes, which are members of the G-proteincoupled receptor family. 7 The two receptors have unique locations and affinities for the endothelins. The A subtype receptor (ET A ) is mainly found in vascular smooth muscle cells as well as myocardium, myometrium and adrenal cortex. 8 8 ET A is encoded by the type A endothelin receptor (EDNRA) gene, which is a strong candidate gene for BP regulation. However, the few previously published candidate gene studies of EDNRA have in general been of small size, and most have typed only one polymorphism in the gene. Consequently, there is at present no consensus regarding the involvement of common genetic variation in the EDNRA gene in BP regulation. We have performed a large-scale, family-based genetic association study investigating the role of polymorphisms in the EDNRA gene and BP measured as a quantitative trait, which has utilized ambulatory monitoring to maximize the accuracy of phenotyping.
Methods
The collection strategy of this family study has been described previously. 9 Briefly, families were ascertained between 1993 and 1997 through a proband with essential hypertension. The proband was required to have had an ABPM (either on or off treatment) with mean daytime systolic blood pressure (SBP)4140 mm Hg and mean daytime diastolic blood pressure (DBP)490 mm Hg; or to have had multiple office BP readings taken by their family practitioner greater than 160 mm Hg systolic and 95 mm Hg diastolic; or to be taking two or more antihypertensive drugs for the control of BP. Secondary hypertension was excluded using the standard screening protocol applied in the hypertension clinic, reinforced by further investigations if required. To be suitable for the study, families were required to consist of at least three siblings (including the proband) clinically assessable for BP if at least one parent of the sibship was available to give blood for DNA analysis, and to consist of at least four assessable siblings (including the proband) if no parent was available for DNA analysis. Qualifying sibships could be either in the generation of the proband or his/her offspring, and there was no requirement for the sibship to contain additional members affected with hypertension (though this was not an exclusion criterion). Where members of the sibship were found to be hypertensive (using identical criteria to those applied in the probands), families were extended and the spouses and offspring of hypertensive sibs collected. Thus, the majority of the individuals in the family collection have BPs within the normal range, and the family collection includes some extended families, though most are nuclear families. The study received ethical clearance from the appropriate review committees, and corresponded with the principles of the Declaration of Helsinki. All participants gave informed consent to participate in the study.
BP was measured using ambulatory monitoring for a period of 24 h in all subjects willing to undergo monitoring, using the A&D TM2421 monitor (Takeda Medical, Japan) according to a previously described protocol. 10 In brief, the monitor was programmed to record BP every half hour during the daytime and every hour during the night, and a recording was considered of satisfactory technical quality if greater than 20 daytime ambulatory data points were available for analysis. Participants completed diaries indicating when they had gone to bed in order that day and night readings could be individually designated. Owing to the possibility of sleep disturbance with cuff inflation, participants were given the option to turn the monitor off during the night and on again to complete the 24-h recording when they got up the following morning. A full clinical history was taken, which included the subject's medical history and lifestyle factors including consumption of alcohol and tobacco, and habitual physical exercise. Anthropometric measurements including height, weight, waist and hip measurement were made (waist measured at the natural waist, and hip measured at the level of the greater trochanters). Blood was drawn into a variety of anticoagulants for plasma and DNA analysis. A total of 1425 individuals from 248 families participated in the study.
The EDNRA gene maps to chromosome 4q31.22 and spans over 63.97 kb of genomic DNA. It contains eight exons. Haploview (www.broad.mit.edu/mpg/ haploview/) analysis of the HapMap data for the samples of Northern and Western European ancestry (CEU samples) showed the EDNRA gene to consist of four major haplotype blocks (www.hapmap.org). We selected one common single nucleotide polymorphism (SNP) from each haplotype block: rs1801708 (referred to in previous studies as G-231A) from the 5 0 untranslated region of the gene; rs1568136 (an MseI restriction fragment length polymorphism, RFLP) from intron 2; the synonymous rs5333 SNP (referred to in previous studies as H323H or A958G) from exon 6 and the rs5335 SNP from the untranslated portion of the eighth and final exon (rs5335 has also been referred to by previous authors as C þ 211G or C þ 70G, as per numbering schemes from either the first nucleotide or the first untranslated nucleotide in exon 8 respectively). The structure of the EDNRA gene and the relative physical positions of the SNPs are shown in Figure 1 . All SNPs were genotyped by PCR followed by RFLP analysis using primers and conditions available as supplementary information from our website (http://www.ncl.ac.uk/ihg/research/ ednraSuppInfo.doc). 25 ng of genomic DNA was amplified in a total reaction volume of 10 ml. Amplification was performed by initial denaturation at 94 1C for 3 min followed by 30 cycles of denaturation at 93 1C for 1 min, annealing at the respective temperatures for 1 min and extension at 72 1C for 1 min. PCR amplicons were checked on agarose gel prior to restriction digestion with one unit of restriction enzyme, followed by electrophoresis on a 3% agarose gel. Control individuals of known genotype were included in every plate, and 100 randomly selected samples were genotyped twice for each polymorphism, with an estimated genotyping error rate of o1%. Genotyping was carried out blinded to phenotypic information and allele calling was carried out by two different investigators. Mendelian inheritance of all the genotypes was checked using PEDSTATS; 11 additional checks on genotyping accuracy were carried out using the error-checking option in MERLIN. 12 Haplotype frequencies in the population were estimated using FUGUE. 13 BP data were log-transformed to approximately Normalize the distribution. The data were then adjusted for age and sex. About one-fifth of the participants with ambulatory monitoring data available were taking antihypertensive drugs at the time they were monitored; to maximize our power to detect an effect of the EDNRA gene we incorporated these participants in the analyses, and corrected for drug treatment. Rather than make a fixed arbitrary adjustment as suggested by Tobin et al.
14 we chose to estimate the effect of diuretic and b-blocker treatment (specified as present or absent) on each of our corrected variables by comparing the hypertensive individuals with and without drug treatment. A total of 34% of hypertensive individuals were receiving diuretics, 32% b-blockers and 13% both treatments. The effects of the drugs appeared to be additive and of approximately equal magnitude. Therefore, twice the correction factor was added to the BPs of those individuals taking both a diuretic and b-blocker as was added to the BPs of those individuals taking either drug alone. None of the non-hypertensive individuals were receiving these drug treatments. Insufficient numbers of participants were taking other classes of antihypertensive drugs for precise class-specific adjustments to be made, so those individuals were excluded from the treatmentadjusted analyses.
Identity-by-descent vectors were calculated using MERLIN, and quantitative trait association analysis was conducted for individual SNPs as previously described using QTDT. 15 We examined association between genotype and hypertension affection status using logistic regression. In these qualitative analyses, participants with clinic BPs o140/90 (after adjustment for age and sex) were judged to be controls, while those with clinic BPs4140/90 but who did not meet the strict criteria for hypertension affection status pre-specified in the study were judged to be of indeterminate status.
Results
Characteristics of the individuals participating are summarized in Table 1 . A total of 52% of the sample were female and 36% were classified as hypertensive. As expected given the selection of families through a hypertensive proband, ambulatory BPs tended to be higher than would be expected in a non-selected population. Quantitative daytime recordings of ambulatory BP were available in 958 people, with on-treatment recordings available in a further 224. Due to participants electing to switch off the monitor at night, fewer night recordings were available: quantitative night recordings were available in 770 people with on-treatment recordings available in a further 162. The median family size was five people, 60% of families comprising between four and six genotyped and phenotyped members. 71% of families were two-generation and 29% were three generation. 
EDNRA gene and ambulatory blood pressure T Rahman et al
Genotyping was successful for over 95% of available samples for all SNPs. All four SNPs were in Hardy-Weinberg equilibrium at the 0.05 level, and allele frequencies were in good agreement with previous available information. Heterozygosities ranged from 36 to 48%. Linkage disequilibrium between the markers was moderate, as expected given the marker selection strategy, and for those markers that were typed in the HapMap project (rs1568136, rs5333 and rs5335), the strength of linkage disequilibrium we observed between each pair of markers was in good agreement with the HapMap data for the CEU population. The estimated haplotype frequencies of greater than 2% frequency defined by the four typed markers in this population were in good agreement with the CEU HapMap data. Nine such haplotypes accounted for 86.6% of the variation present. Details of the genotype and allele frequencies, linkage disequilibrium coefficients and estimated haplotype frequencies are available on our website (www.ncl.ac.uk/ihg/ research/ednraSuppInfo.doc).
There was no significant evidence of association between genotypes at the rs1801708, rs1568136 or rs5333 (G-231A, MseI or H323H) polymorphisms and BP levels (P40.1 for all; data not shown). There was significant association between genotypes at the EDNRA rs5335 (C þ 70G) SNP and mean and DBPs during the night (Table 2) . At the rs5335 SNP, 498 individuals were of G/G genotype, 646 of C/G genotype and 192 of C/C genotype. There were similar but marginally less significant effects on daytime SBP, DBP and mean BP, and on night SBP. The associations appeared to be codominant. Each C allele was associated with a 1.24% (0.641) lower night SBP (P ¼ 0.051), a 1.64% (0.71) lower night DBP (P ¼ 0.021) and a 1.51% (0.64) lower mean night BP (P ¼ 0.017). The stronger association with the night-time values may be due to the higher heritability of night than day BPs: for example, the heritability of adjusted log-transformed daytime SBP in these families was 10.4% whereas the heritability of night SBP was 25.8%. This observation presumably arose because of a smaller degree of random environmental effect on BP during the night. The contribution of rs5335 genotype to the total variability of BP was, however, small-around 1-2% for each of the phenotypes with which it was associated. We also examined the relationship between genotype and hypertension affection status because we were able to include more treated individuals, who were not taking b-blockers or diuretics, in that analysis (N ¼ 1211). In keeping with the quantitative findings, a codominant genetic model was tested. Among those of CC genotype, 34.7% were hypertensive, among those of CG genotype 37.9% and among those with GG genotype 42.4%. This yielded an odds ratio for hypertension of 1.19 (95% confidence interval 1.00-1.41; P ¼ 0.05) per G allele carried.
Discussion
We have shown a small effect of the rs5335 (C þ 70G) SNP of the EDNRA gene on ambulatory BP. Each G allele was associated with around a 1.5 mm Hg higher diastolic pressure and 2.5 mm Hg higher EDNRA gene and ambulatory blood pressure T Rahman et al systolic pressure. There was a consistent trend in this direction for SBP and DBP, both by day and by night. When we considered hypertension affection status, each G allele was found to increase the risk of hypertension by about 20%. We calculated that rs5335 genotype was responsible for around 1% of the total variability of BP; thus, rs5335 genotype may account for 2.5-5% of the genetic component to BP variation in the population. Some previous studies have evaluated the relationship between polymorphisms of EDNRA and cardiovascular phenotypes, though the number of patients studied to date remains too small for a meaningful formal meta-analysis to be conducted. Three previous studies have compared allele frequencies in hypertensives and control subjects. Stevens and Brown 16 found no association between the rs5333 (H323H) polymorphism in a study of 100 cases and 100 controls. Benjafield et al. 17 studied 155 hypertensives and 245 controls for the rs1801708 (G-231A) polymorphism; they also studied a C þ 1363T SNP which is located downstream of rs5335 (C þ 70G) in the untranslated region of the eighth exon. They found no association between the G-231A SNP and hypertension, but a borderline significant association (P ¼ 0.019) between the C allele of the C þ 1363T SNP and hypertension. Although we did not type the C þ 1363T SNP, strong linkage disequilibrium between C þ 1363T and the rs5335 SNP showing evidence of association in the present study has been demonstrated in previous studies. Ormezzano et al. 18 typed 146 hypertensive cases and 105 controls for the G-231A and C þ 1363T SNPs (the latter was termed C þ 1222T in that study). No association was observed between genotype at either SNP and hypertension, although the T allele of C þ 1363T was associated with a lower baroreflex sensitivity most marked in hypertensives. 18 Two previous studies, both smaller than the present investigation and neither utilizing ambulatory monitoring, have investigated the relationship between EDNRA SNPs and BP as a quantitative trait. Iemitsu et al. 19 studied 191 healthy Japanese individuals and typed the rs5333 (H323H) SNP. No significant association between genotype and BP was found; however, that study was small, and actively selected against the inclusion of hypertensive people. 19 A more comprehensive analysis was conducted by Nicaud et al. 20 who typed five SNPs spanning the EDNRA gene and including rs1801708 (G-231A), rs5333 (H323H), rs5335 (C þ 70G) and C þ 1363T, in 773 men who were controls in the ECTIM case-control study of myocardial infarction. These authors found a non-significant trend towards higher SBP in carriers of the G allele of rs5335, and association between higher SBP and the T allele of C þ 1363T (P ¼ 0.043). There were borderline significant trends in the opposite direction for DBP at both these polymorphisms, and so overall there was significant evidence for association between genotype and pulse pressure (P ¼ 0.008 and P ¼ 0.004 respectively). The present larger study, which has utilized ambulatory monitoring, provides more robust evidence of association between the rs5335 SNP and both SBP and DBP. Taken together, the studies consistently suggest that variation in the haplotype block encompassing the 3 0 untranslated region of EDNRA is a significant determinant of BP, possibly via an effect on arterial compliance.
Previous studies suggest possible mechanisms whereby genetic variation in EDNRA might influence BP. EDNRA is overexpressed in the arteries of hypertensive patients, 21 and Campia et al.
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observed an enhanced EDNRA-dependent vasoconstrictor tone in hypertensives, which they suggested might be related to increased production of ET-1. Brown et al. 23 observed an upregulation of ET-1 and the ET A receptor in several animal models of myocardial hypertrophy. There is also evidence that ET-1, via ET A receptor activation, causes hypertension observed in pregnant rats and pre-eclamptic women with chronically reduced uterine perfusion pressure. 24, 25 Pharmacological studies confirm the important role of the ET A receptor in BP regulation. Selective ET A antagonists such as BQ 123, BMS 182874 and FR 139317 block the rise of BP in certain rat models, which shows that hypertension is to some extent dependent on endothelin-related mechanisms. 7, 26, 27 Selective ET A receptor antagonists significantly reduce BP in hypertensive subjects. 28, 29 ET A receptor antagonists cause a greater degree of vasodilatation in forearm vessels of essential hypertensive patients than in normotensive controls, suggesting a predominant role of ET A receptors in the regulation of vascular tone by endogenous ET-1 in hypertension. 30 Since the rs5335 SNP is untranslated, it seems likely that this SNP (or a neighbouring causative SNP in linkage disequilibrium) principally affects mRNA processing, with carriage of the less common C allele resulting in reduced expression of the receptor and thus lower BP. Further studies, possibly involving the quantification of allele expression imbalance in mRNA from heterozygotes at the rs5335 SNP, will be necessary to investigate this hypothesis.
Strengths of this study include its large size, its family-based design that alleviates concerns about population stratification as a cause of spurious results and perhaps most importantly its use of ambulatory monitoring to increase the power to detect small genetic effects. A possible limitation of our result is that the association between genotype at rs5335 and BP that we have described accounts for only a small proportion of the population variability of the trait. However, this result provides the strongest evidence yet available that natural variation in the endothelin signal transduction pathway has effects on BP variability. Future studies of other genes in the endothelin pathway may reveal larger-sized effects; it will also be of great interest to evaluate the rs5335 SNP in pharmacogenetic studies.
What was previously known on this subject K The type A endothelin receptor has a strong biological argument in its favour as a candidate gene for high blood pressure. K Previous studies have not established whether genetic variation in EDNRA is associated with hypertension.
What this study adds K A polymorphism rs5335 (also called C+70G) of the EDNRA gene increases blood pressure by 1-2%. Carriers of the variant allele have a 20% higher risk of hypertension. K To detect this small effect, it was necessary to use ambulatory monitoring to define the hypertensive phenotype. This illustrates that the additional power of ambulatory monitoring may be useful in genetic studies of blood pressure.
